OOIR: Observatory of International Research

Papers

(The TQCC of European Journal of Health Economics is 5. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)

Article	Citations
Education and medication use later in life and the role of intelligence	88
Beyond 10-year lead-times in EQ-5D-5L: leveraging alternative lead-times in willingness-to-accept questions to capture preferences for worse-than-dead states and their implication	53
Pragmatic randomized controlled trial comparing a complex telemedicine-based intervention with usual care in patients with chronic conditions	37
Psychometric properties and general population reference values for PROMIS Global Health in Hungary	32
Comparing the measurement properties of the EQ-5D-Y-3L, EQ-5D-Y-5L and CHU9D in children and adolescents: a measurement property study	29
Correction to: Geographic distribution of physicians in Portugal	28
The hidden cost of sophistication: economic complexity and obesity	24
Patient-level cost analysis of subfertility pathways in the Dutch healthcare system	23
Risk equalization and prevention	22
Cost-effectiveness of adding oseltamivir to primary care for influenza-like-illness: economic evaluation alongside the randomised controlled ALIC4E trial in 15 European countries	22
Should Scotland provide genome-wide sequencing for the diagnosis of rare developmental disorders? A cost-effectiveness analysis	22
Cost-effectiveness of transcatheter aortic valve implantation in patients at low surgical risk in France: a model-based analysis of the Evolut LR trial	22
Domain-specific discounting of health and money: implications for health technology assessment	21
Comparative cost-effectiveness of nivolumab first-line and second-line therapy for advanced esophageal cancer in Japan	19
Cost awareness among intensivists in their daily clinical practice: a prospective multicentre study	19
Prescription opioids and economic hardship in France	19
Replay to: Comparison of EQ-5D-5 L and EORTC QLU-C10D utilities in gastric cancer patients	18
Setting incentives right with long-term risk adjustment	18
Nothing about us, without us? A reflection on and call for involving children in the process of valuing child health	18
From test to rest: evaluating socioeconomic differences along the COVID-19 care pathway in the Netherlands	17
Primary care services and emergency department visits in blended fee-for-service and blended capitation models: evidence from Ontario, Canada	16
Workload and short sickness absences in a cohort of Finnish hospital employees	16
Expensive today but cheaper tomorrow: lifetime costs of an active middle ear implant compared to alternative treatment options	16
Economic assessment of abemaciclib for the adjuvant treatment of luminal HER2- breast cancer from the perspective of the Spanish health system	15
Multinational stakeholder engagement to inform future development and refinement of the EuroQol toddler and infant populations (EQ-TIPS)	15

Impact of postoperative in-hospital continuous vital sign monitoring on healthcare costs, resource utilization and labor market outcomes	14
Health-related quality of life in patients with alcohol use disorder: comparing instruments and mapping from clinical measures to preference-based measures	14
Informing decisions in light of parameter uncertainty – an economic evaluation of the adjuvanted recombinant herpes zoster vaccine in Sweden	14
On spillovers in economic evaluations: definition, mapping review and research agenda	14
Cost-effectiveness of encorafenib with binimetinib in unresectable or metastatic BRAF-mutant melanoma	13
Mobile money and households’ ability to respond to health shocks in Africa: Evidence from Madagascar	13
The EORTC QLU-C10D is a valid cancer-specific preference-based measure for cost-utility and health technology assessment in the Netherlands	13
Trends in NICE technology appraisals of non-small cell lung cancer drugs over the last decade	13
Breaking the rules: decision-making under absolute resource constraints	12
Availability of pharmacological treatments for multiple myeloma in Spain	12
Antivirals to prepare for surges in influenza cases: an economic evaluation of baloxavir marboxil for the Netherlands	12
Comparing EQ-5D-5L and SF-6Dv2 utilities with QLU-C10D utilities in hematologic cancer patients	12
Life-cycle health effects of compulsory schooling	12
Healthcare resource utilization and costs of letermovir for cytomegalovirus-prophylaxis after allogeneic hematopoietic cell transplantation in a real-world, multi-centre study in Germany	12
Correction: AOTMiT reimbursement recommendations compared to other HTA agencies	12
The causal effect of catastrophic health expenditure on poverty in Poland	12
How perceptions of bone marrow donation costs affect donation behavior: survey evidence from a large donor registry	12
Analyzing nurses’ decisions to leave their profession—a duration analysis	12
The trade-off between health system resiliency and efficiency: evidence from COVID-19 in European regions	11
The cost-effectiveness of value-based insurance design initiatives in managing cardiometabolic diseases: a systematic review	11
Is next generation sequencing for the diagnosis of rare diseases worth its cost? A user-based approach to valuation	11
Do EQ-5D-Y-3L value sets have common properties, and how do they compare to EQ-5D-5L value sets?	11
Costs attributable to hypercholesterolemia in a single period and over the life cycle	11
Benefits beyond health in the willingness to pay for a quality-adjusted life-year	11
Economic value of diastasis repair with the use of mesh compared to no intervention in Italy	10
Adverse selection and consumer inertia: empirical evidence from the Dutch health insurance market	10
Estimating loss in capability wellbeing in the first year of the COVID-19 pandemic: a cross-sectional study of the general adult population in the UK, Australia and the Netherlands	10
The social value of gambling: surplus estimates by gambling types for France	10
Healthcare costs of foodborne diseases in the United States: an analysis using electronic health records	10
Time value of informal care of people with alzheimer’s disease in Spain: a population-based analysis	10
Sex differences in care complexity and cost of cardiac-related procedures as a basis for improving hospital payments systems	10
A principled approach to non-discrimination in cost-effectiveness	10
The impacts of working from home on individual health and well-being	10
Cancer specific health utilities - QLU-C10D country value sets for Belgium, Hungary, Portugal and the Republic of Korea – an international valuation study	9
Changes in spending, quality indicators, and provider experiences following the introduction of a population-based payment model in dutch primary care: a mixed methods evaluation	9
Modeling European health systems: an ideal chain of services	9
Valuation of the EQ-5D-3L in Jordan	9
Estimating QALYs in adults with cerebral palsy: mapping the San Martin scale to the EQ-5D-5L for economic evaluation	9
Does prescribing apixaban or rivaroxaban versus warfarin for patients diagnosed with atrial fibrillation save health system costs? A multivalued treatment effects analysis	9
Do mobile hospital teams in residential aged care facilities increase health care efficiency: an evaluation of French residential care policy	9
How tax structures for retail cannabis shape cannabis use among youth and young adults: evidence from a volumetric choice experiment	9
Evaluating hospital performance	9
Does chronic disease coverage for outpatient care affect healthcare utilization and expenditures in China? Evidence from an administrative claim dataset	9
Demographic and health impacts of women’s bodily autonomy: switching prescription requirements for emergency contraceptives	9
Pharmacy cost groups for the German morbidity-based risk compensation scheme	9
Measuring and decomposing income inequalities in child and adolescent mental health in the UK	9
Does medial tourism promote growth in healthcare sector?	9
Alcohol prices, the April effect, and the environment, in violence-related injury in England and Wales	8
Change in healthcare resource use and associated costs of patients with metastatic lung cancer between 2013 and 2021: an observational study from the French national health data system	8
Cost-effectiveness analysis (CEA) of ovarian cancer preventive strategies for women with BRCA1/2 pathogenic variants: the role of surveillance	8

Scales and size-quality outcomes in adult learning disability residential care: evidence from the UK	8
The ACA Medicaid expansions and abortion rates among young adults	8
Tenders for generics and biosimilars: a challenging purchasing policy	8
Modeling the potential efficiency of a blood biomarker-based tool to guide pre-hospital thrombolytic therapy in stroke patients	8
Significant healthcare burden and life cost of spinal muscular atrophy: real-world data	8
Assessment of health state utilities associated with adult and pediatric acid sphingomyelinase deficiency (ASMD)	7
Recovery of suspended reimbursements of high-cost drugs subjected to monitoring registries and negotiated agreements (MEAs): a tool for governance and clinical appropriateness in the Italian reality	7
Costs of productivity loss up to two years after ischaemic stroke	7
Forward-looking Behavior in Health Insurance	7
How are patient inputs considered in HTA? A thematic document analysis of NICE ultra-rare disease appraisals	7
The pass-through of excise taxes to market prices of heated tobacco products (HTPs) and cigarettes: a cross-country analysis	7
Challenges for health systems seeking to embrace virtual health care for population health	7
Measuring outcomes for loneliness research: examining the appropriateness of the EQ-5D-5 L and EQ-HWB	7
Economics of hypothalamic obesity in patients with craniopharyngioma and other rare sellar/suprasellar tumors	7
Economic evaluation on dental caries preventive interventions for Australian children using a priority-setting approach	7
Cost-utility of cochlear implantation in single-sided deafness and asymmetric hearing loss: results of a randomized controlled trial	7
Self-interest, positional concerns and distributional considerations in healthcare preferences	7
Public preferences for saving lives versus life-years: evidence from a person-trade-off experiment in 12 countries during the COVID-19 pandemic	7
The link between physician motivation and care	7
Obtaining preference scores for an abbreviated self-completion version of the Teen-Addiction Severity Index (ASC T-ASI) to value therapy outcomes of systemic family interventions: a discrete choice ex	7
Cost-effectiveness of two online interventions supporting self-care for eczema for parents/carers and young people	7
The health and long-term care costs in the last year of life in The Netherlands	6
Referring physicians' intention to use hospital report cards for hospital referral purposes in the presence or absence of patient-reported outcomes: a randomized trial	6
Paid and unpaid productivity losses across 28 European countries due to excess deaths and COVID-19 deaths from 2020 to 2023	6
Unravelling heterogeneity in efficiency measurements: a case study of public hospitals in Spain	6
Impact of the introduction of the AMNOG law on launch delays of new drugs in Germany: a comment	6
Personnel shortages and the provision of long-term care: an empirical analysis of German nursing homes	6
Trends and drivers of pharmaceutical expenditures from systemic anti-cancer therapy	6
Assessing Taiwan’s pay-for-performance program for diabetes care: a cost–benefit net value approach	6
Inpatient care utilisation and expenditure associated with objective physical activity: econometric analysis of the UK Biobank	6
Health inequalities and subjective wellbeing	6
Does diagnostic testing always decrease antibiotics prescriptions?	6
Modeling European health systems: a theoretical exercise	6
Generating EQ-5D-3L health utility scores from the Edinburgh Postnatal Depression Scale: a perinatal mapping study	6
Does health technology assessment compromise access to pharmaceuticals?	6
Disclosing the ‘Big C’: what does cancer survivorship signal to employers?	6
A critical review of the use of R2 in risk equalization research	5
A hearing bolt-on item increased the measurement properties of the EQ-5D-5L in a community-based hearing loss screening program	5
Ex ante evaluation of risk adjustment models for prospective provider payment: a conceptual framework and empirical application	5
Estimating cost savings from reducing antibiotic overprescription in european general practices	5
Special FDA designations for drug development: orphan, fast track, accelerated approval, priority review, and breakthrough therapy	5
Mapping of the EORTC QLQ-LC43 to EQ-5D-5 L index in patients with lung cancer: comparison of traditional regression models with machine learning technique	5
Total costs of different lines of treatment in diffuse large B-cell lymphoma in Denmark – a real-world data analysis	5
Willingness to pay for a quality adjusted life year across different time horizons: direct elicitation in Quebec	5
Translating the EORTC CAT core and the QLQ-C30 to the EQ-5D-5L in patients with metastatic breast cancer: A comparison of direct and indirect mapping algorithms	5
Time preferences and COVID-19 vaccination uptake	5
Obesity and metabolic state are associated with increased healthcare resource and medication use and costs: a Finnish population-based study	5
One week versus three to five weeks of plaster cast immobilization for nonreduced distal radius fractures, a cost effectiveness analysis embedded in a stepped wedge cluster randomized controlled trial	5
Comparing EQ-5D-5L, PROPr, SF-6D and TTO utilities in patients with chronic skin diseases	5
Correction: Lifetime direct healthcare costs of treating colorectal cancer: a systematic review	5
A systematic review of economic models comparing in-centre haemodialysis interventions: challenges for demonstrating cost-effectiveness in the context of high background dialysis costs	5
Breaking the habit: a systematic review of the cost-effectiveness of non-pharmacological and combined interventions for smoking cessation in Europe	5
Productivity costs associated with premature deaths due to acute myocardial infarction in Spain: analysis from 2013 to 2022	5
The societal cost of ‘unwanted’ loneliness in Spain	5
The effect of displaying laboratory test prices on physicians’ ordering behaviour: a systematic review of European studies	5
The performance of the EQ-HWB-S as a measure of quality-of-life of caregivers in families that have experienced adverse events	5
Long-term costs associated with healthcare use of people with cancer in Scotland	5
Health state utilities associated with X-linked retinitis pigmentosa (XLRP)	5
A cross-country comparison of the psychometric performance of SF-6Dv2 and EQ-5D-5L	5
Cost-effectiveness analysis of the covered endovascular reconstruction of the aortic bifurcation versus kissing stents and open surgical repair for the treatment of aorto-iliac occlusive disease	5
Cost-effectiveness and cost-utility analysis of a nurse-led, transitional care model to improve care coordination for patients with cardiovascular diseases: results from the “Cardiolotse” study	5
Economic burden of eosinophilic esophagitis in the first year after diagnosis in Spain: A direct medical cost analysis	5
Long-term effectiveness and cost-effectiveness of testing for alemtuzumab antidrug antibodies to guide treatment in multiple sclerosis: a modelling study	5